Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Net revenue:
Total net revenue		$ 114,760	$ 116,275	$ 211,253	$ 223,717
Cost of revenue:
Total cost of revenue	[1]	71,793	73,648	133,689	141,566
Gross profit		42,967	42,627	77,564	82,151
Operating expenses:
Research and development	[2]	14,641	14,697	28,733	29,079
Selling and marketing		13,586	13,233	24,381	24,504
General and administrative		12,035	10,716	23,927	22,176
Total operating expenses		40,262	38,646	77,041	75,759
Income from operations		2,705	3,981	523	6,392
Loss on equity method investment, net		(699)	(832)	(1,067)	(1,172)
Other expense, net		(2,831)	(2,490)	(5,389)	(5,158)
Income (loss) before provision for income taxes		(825)	659	(5,933)	62
Provision for income taxes		1,049	480	1,390	911
Net income (loss)		$ (1,874)	$ 179	$ (7,323)	$ (849)
Net income (loss) per share - basic		$ (0.02)	$ 0.00	$ (0.08)	$ (0.01)
Net income (loss) per share - diluted		$ (0.02)	$ 0.00	$ (0.08)	$ (0.01)
Weighted average common shares used in computing net loss per share:
Basic		94,567	91,761	94,048	91,299
Diluted		94,567	93,932	94,048	91,299
Net income (loss)		$ (1,874)	$ 179	$ (7,323)	$ (849)
Foreign currency translation adjustment		2,790	(108)	(865)	123
Comprehensive income (loss)		916	71	(8,188)	(726)
Products
Net revenue:
Total net revenue	[3]	63,269	60,721	107,892	113,480
Cost of revenue:
Total cost of revenue		39,248	35,520	68,098	67,029
Services
Net revenue:
Total net revenue	[4]	51,491	55,554	103,361	110,237
Cost of revenue:
Total cost of revenue		$ 32,545	$ 38,128	$ 65,591	$ 74,537

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment, of $9,916 and $15,823 during the three and six months ended December 31, 2022, respectively, and $6,203 and $14,248 during the three and six months ended December 31, 2021, respectively.

[2] Includes charge back to the China joint venture, an equity method investment, related to a research and development project of $487 and $1,266 during the three and six months ended December 31, 2022, respectively, and $415 and $994 during the three and six months ended December 31, 2021, respectively.

[3] Includes sales to the China joint venture, an equity method investment, of $16,715 and $25,584 during the three and six months ended December 31, 2022, and $8,816 and $14,735 during the three and six months ended December 31, 2021, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment, of $2,494 and $5,451 during the three and six months ended December 31, 2022, respectively, and $2,679 and $5,494 during the three and six months ended December 31, 2021, respectively. See Note 14.